Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, carboplatin, and nab-paclitaxel as neoadjuvant therapy for oral cavity or oropharyngeal cancer
NCT04718415Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in oral cavity squamous cell carcinoma (OCSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Sun Yat-sen Memorial Hospital. Started Jan 2021; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT04718415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718415.